竞争性内源RNA在胆管细胞癌发生发展中的作用

徐宝麟; 成雨; 魏勇

doi:10.3969/j.issn.1001-5256.2022.11.044

竞争性内源RNA在胆管细胞癌发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2022.11.044

滨州医学院烟台附属医院肝胆胰脾外科，山东烟台 264100

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：徐宝麟负责资料收集与分析，撰写论文；魏勇、成雨负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
魏勇，weiyonglancet@163.com

计量
- 文章访问数: 343
- HTML全文浏览量: 92
- PDF下载量: 23
- 被引次数: 0
出版历程
- 收稿日期: 2022-03-13
- 录用日期: 2022-05-15
- 出版日期: 2022-11-20

The role of competitive endogenous RNA in the development of cholangiocarcinoma

Department of Hepatobiliary, Pancreatic and Splenic Surgery, The Affiliated Yantai Hospital of Binzhou Medical University, Yantai, Shandong 264100, China

More Information

Corresponding author: WEI Yong, weiyonglancet@163.com(ORCID: 0000-0002-3279-9465)

摘要

摘要: 竞争性内源RNA是能够竞争性结合miRNA的一类转录产物，主要包括长链非编码RNA及环状RNA等，参与多种肿瘤的发生过程。胆管癌恶性程度高，预后差，治疗手段有限，发病机制复杂。竞争性内源RNA，特别是长链非编码RNA和环状RNA，能够通过影响胆管癌细胞的生物学行为、细胞代谢、炎症过程、上皮-间质转化过程影响胆管癌的发生发展。本文对长链非编码RNA与环状RNA在胆管细胞癌发生中的作用进行综述，以期进一步阐明胆管癌的发病机制。
- 胆管肿瘤 /
- RNA /
- RNA, 长链非编码
Abstract: Cholangiocarcinoma is a highly malignant tumor with a poor prognosis, limited treatment options, and complicated pathogenesis. Competitive endogenous RNA is a kind of transcripts that can competitively bind miRNA, including long non-coding RNA and circular RNA. Competitive endogenous RNA is known to be involved in a variety of tumors. It can modulate the occurrence and development of cholangiocarcinoma by regulating the biological behavior, cell metabolism, inflammatory process and epithelial-mesenchymal transition of cholangiocarcinoma cells. Here we review recent research progress on the role of long non-coding RNA and circular RNA in cholangiocarcinoma to help better understand the pathogenesis of cholangiocarcinoma.
- Bile Duct Neoplasms /
- RNA /
- RNA, Long Noncoding

HTML全文

参考文献(31)

[1]	YU Y, CHEN Q, ZHANG X, et al. Long noncoding RNA ANRIL promotes the malignant progression of cholangiocarcinoma by epigenetically repressing ERRFI1 expression[J]. Cancer Sci, 2020, 111(7): 2297-2309. DOI: 10.1111/cas.14447.
[2]	DU C, LI DQ, LI N, et al. DDX5 promotes gastric cancer cell proliferation in vitro and in vivo through mTOR signaling pathway[J]. Sci Rep, 2017, 7: 42876. DOI: 10.1038/srep42876.
[3]	XUE Y, JIA X, LI L, et al. DDX5 promotes hepatocellular carcinoma tumorigenesis via Akt signaling pathway[J]. Biochem Biophys Res Commun, 2018, 503(4): 2885-2891. DOI: 10.1016/j.bbrc.2018.08.063.
[4]	ZHANG M, WENG W, ZHANG Q, et al. The lncRNA NEAT1 activates Wnt/β-catenin signaling and promotes colorectal cancer progression via interacting with DDX5[J]. J Hematol Oncol, 2018, 11(1): 113. DOI: 10.1186/s13045-018-0656-7.
[5]	CONTAT C, ANCEY PB, ZANGGER N, et al. Combined deletion of Glut1 and Glut3 impairs lung adenocarcinoma growth[J]. Elife, 2020, 9. DOI: 10.7554/eLife.53618.
[6]	SUN Q, GONG X, WU J, et al. Effect of lncRNA PVT1/miR186/KLF5 axis on the occurrence and progression of cholangiocarcinoma[J]. Biomed Res Int, 2021, 2021: 8893652. DOI: 10.1155/2021/8893652.
[7]	TU J, WU F, CHEN L, et al. Long non-coding RNA PCAT6 Induces M2 polarization of macrophages in cholangiocarcinoma via modulating miR-326 and RhoA-ROCK signaling pathway[J]. Front Oncol, 2020, 10: 605877. DOI: 10.3389/fonc.2020.605877.
[8]	HUANG L, JIANG X, KANG P, et al. Long non-coding RNA NNT-AS1 functions as an oncogenic gene through modulating miR-485/BCL9 in cholangiocarcinoma[J]. Cancer Manag Res, 2019, 11: 7739-7749. DOI: 10.2147/CMAR.S207801.
[9]	LIN H, YANG L, TIAN F, et al. Up-regulated LncRNA-ATB regulates the growth and metastasis of cholangiocarcinoma via miR-200c signals[J]. Onco Targets Ther, 2019, 12: 7561-7571. DOI: 10.2147/OTT.S217676.
[10]	YU Y, ZHANG M, LIU J, et al. Long non-coding RNA PVT1 promotes cell proliferation and migration by silencing ANGPTL4 expression in cholangiocarcinoma[J]. Mol Ther Nucleic Acids, 2018, 13: 503-513. DOI: 10.1016/j.omtn.2018.10.001.
[11]	XU Y, YAO Y, LENG K, et al. Long non-coding RNA UCA1 indicates an unfavorable prognosis and promotes tumorigenesis via regulating AKT/GSK-3β signaling pathway in cholangiocarcinoma[J]. Oncotarget, 2017, 8(56): 96203-96214. DOI: 10.18632/oncotarget.21884.
[12]	YANG L, DAI F, TANG L, et al. Macrophage differentiation induced by PMA is mediated by activation of RhoA/ROCK signaling[J]. J Toxicol Sci, 2017, 42(6): 763-771. DOI: 10.2131/jts.42.763.
[13]	GU Y, ZHU Z, PEI H, et al. Long non-coding RNA NNT-AS1 promotes cholangiocarcinoma cells proliferation and epithelial-to-mesenchymal transition through down-regulating miR-203[J]. Aging (Albany NY), 2020, 12(3): 2333-2346. DOI: 10.18632/aging.102747.
[14]	XU Y, YAO Y, JIANG X, et al. SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma[J]. J Exp Clin Cancer Res, 2018, 37(1): 81. DOI: 10.1186/s13046-018-0747-x.
[15]	LI Z, JIANG X, HUANG L, et al. Up-regulation of ZFAS1 indicates dismal prognosis for cholangiocarcinoma and promotes proliferation and metastasis by modulating USF1 via miR-296-5p[J]. J Cell Mol Med, 2019, 23(12): 8258-8268. DOI: 10.1111/jcmm.14698.
[16]	WANG H, WANG L, TANG L, et al. Long noncoding RNA SNHG6 promotes proliferation and angiogenesis of cholangiocarcinoma cells through sponging miR-101-3p and activation of E2F8[J]. J Cancer, 2020, 11(10): 3002-3012. DOI: 10.7150/jca.40592.
[17]	LV Y, XIAO J, LIU J, et al. E2F8 is a potential therapeutic target for hepatocellular carcinoma[J]. J Cancer, 2017, 8(7): 1205-1213. DOI: 10.7150/jca.18255.
[18]	ROY S, GLASER S, CHAKRABORTY S. Inflammation and progression of cholangiocarcinoma: role of angiogenic and lymphangiogenic mechanisms[J]. Front Med (Lausanne), 2019, 6: 293. DOI: 10.3389/fmed.2019.00293.
[19]	LI X, LIU R, WANG Y, et al. Cholangiocyte-derived exosomal lncRNA H19 promotes macrophage activation and hepatic inflammation under cholestatic conditions[J]. Cells, 2020, 9(1): 190. DOI: 10.3390/cells9010190.
[20]	WANG WT, YE H, WEI PP, et al. LncRNAs H19 and HULC, activated by oxidative stress, promote cell migration and invasion in cholangiocarcinoma through a ceRNA manner[J]. J Hematol Oncol, 2016, 9(1): 117. DOI: 10.1186/s13045-016-0348-0.
[21]	KRISTENSEN LS, ANDERSEN MS, STAGSTED L, et al. The biogenesis, biology and characterization of circular RNAs[J]. Nat Rev Genet, 2019, 20(11): 675-691. DOI: 10.1038/s41576-019-0158-7.
[22]	TANG Q, HANN SS. Biological roles and mechanisms of circular RNA in human cancers[J]. Onco Targets Ther, 2020, 13: 2067-2092. DOI: 10.2147/OTT.S233672.
[23]	LI D, TANG Z, GAO Z, et al. Circular RNA CDR1as exerts oncogenic properties partially through regulating MicroRNA 641 in cholangiocarcinoma[J]. Mol Cell Biol, 2020, 40(15): e00042-20. DOI: 10.1128/MCB.00042-20.
[24]	XU Y, GAO P, WANG Z, et al. Circ-LAMP1 contributes to the growth and metastasis of cholangiocarcinoma via miR-556-5p and miR-567 mediated YY1 activation[J]. J Cell Mol Med, 2021, 25(7): 3226-3238. DOI: 10.1111/jcmm.16392.
[25]	ZHAO X, ZHANG X, ZHANG Z, et al. Comprehensive circular RNA expression profiling constructs a ceRNA network and identifies hsa_circ_0000673 as a novel oncogene in distal cholangiocarcinoma[J]. Aging (Albany NY), 2020, 12(22): 23251-23274. DOI: 10.18632/aging.104099.
[26]	XU Y, YAO Y, LIU Y, et al. Elevation of circular RNA circ_0005230 facilitates cell growth and metastasis via sponging miR-1238 and miR-1299 in cholangiocarcinoma[J]. Aging (Albany NY), 2019, 11(7): 1907-1917. DOI: 10.18632/aging.101872.
[27]	TU J, CHEN W, ZHENG L, et al. Circular RNA Circ0021205 promotes cholangiocarcinoma progression through mir-204-5p/RAB22A axis[J]. Front Cell Dev Biol, 2021, 9: 653207. DOI: 10.3389/fcell.2021.653207.
[28]	YOU J, WANG X. Circ_HIPK3 knockdown inhibits cell proliferation, migration and invasion of cholangiocarcinoma partly via mediating the miR-148a-3p/ULK1 pathway[J]. Cancer Manag Res, 2021, 13: 3827-3839. DOI: 10.2147/CMAR.S293823.
[29]	SU Y, YU T, WANG Y, et al. Circular RNA circDNM3OS functions as a miR-145-5p sponge to accelerate cholangiocarcinoma growth and glutamine metabolism by upregulating MORC2[J]. Onco Targets Ther, 2021, 14: 1117-1129. DOI: 10.2147/OTT.S289241.
[30]	HENSLEY CT, WASTI AT, DEBERARDINIS RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities[J]. J Clin Invest, 2013, 123(9): 3678-3684. DOI: 10.1172/JCI69600.
[31]	CHEN S, CHEN Z, LI Z, et al. Tumor-associated macrophages promote cholangiocarcinoma progression via exosomal Circ_0020256[J]. Cell Death Dis, 2022, 13(1): 94. DOI: 10.1038/s41419-022-04534-0.